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Abstract Tumour necrosis factor-K (TNF-K) signals though
two receptors, TNFR1 and TNFR2. TNFR1 has a role in
cytotoxicity, whereas TNFR2 regulates death responses or
proliferation. TNF activates pro-inflammatory transcription
factor nuclear factor-UB (NF-UB) by uncertain signalling
mechanisms. Here we report the contribution of each TNFR
towards the NF-UB activation processes. In human cells
expressing endogenous or exogenous TNFR2, in addition to
TNFR1, we found both TNFRs capable of activating NF-UB, as
measured by IUBK (inhibitor of NF-UB) degradation, electro-
phoretic mobility shift assay and NF-UB gene reporter assays.
TNFR2 activation did not degrade IUBL. However, TNF-effects
on NF-UB activation occurred predominantly through TNFR1,
with TNFR2 activating the transcription factor poorly. ß 2002
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
Tumour necrosis factor-K (TNF) is a pro-in£ammatory cy-
tokine important for functioning of the immune system, tissue
homeostasis and embryonic development. TNF exerts its cel-
lular e¡ects such as di¡erentiation, proliferation and cell sur-
vival or cytotoxicity through signalling of two distinct TNF
receptors, TNFR1 and TNFR2 [1]. Type I TNFR, TNFR1
(also known as p55TNFR, TNFRSF1a, CD120a), has a mo-
lecular mass of 50^60 kDa, whereas TNFR2 (also known as
p75TNFR, TNFRSF1b, CD120b) has a molecular mass of
70^80 kDa. Both receptors are based on four cysteine-rich
repeat domains in their extracellular region and belong to
the extended TNF/nerve growth factor receptor superfamily.
Intracellularly, TNFR1 and TNFR2 are structurally di¡erent,
indicating that the receptors have distinct biological functions.
TNFR1 intracellular sequence contains a death domain motif
that is found in some receptors of the TNF superfamily and
allows the recruitment of death domain-containing adapter
proteins implicated in cell death signalling in many cell types
[2]. Unlike TNFR1, TNFR2 does not contain a death domain
motif but still recruits adapter proteins to perform the recep-
tor’s intracellular signalling activities. As well as being prolif-
erative in some cell types, engagement of TNFR2 has been
found to have pro-apoptotic e¡ects of varying magnitude [3].
TNFR2-mediated apoptosis has been described as by having a
direct e¡ect [4^6], as a ligand passing e¡ect [7,8], as due to
endogenous induction of TNF [9], and as a co-operative e¡ect
with non-triggered TNFR1 [1].
TNF exerts its e¡ects through TNFR1 and TNFR2, which
signal and initiate activation of a multitude of kinase path-
ways [10]. Studies have demonstrated that TNF can also acti-
vate the NF-UB transcription factor that serves as a critical
regulator of inducible expression of many genes [11]. Tran-
scription factor NF-UB belongs to a family of ubiquitously
expressed Rel-related transcription factors and is activated
by proteolytic degradation of inhibitor of NF-UBs (IUBs) in
the cytoplasm of the cell. NF-UB is localised in the nucleus
and sequestered in the cytoplasm of most cells. Sequestration
of NF-UB is regulated by the IUB proteins which binds to NF-
UB and inhibits its transportation to the nucleus to activate
transcription [12].
NF-UB binds an inhibitory protein, IUBK, which regulates
DNA binding and intracellular localisation of NF-UB [13,14].
On binding of TNF to TNFRs, the signal may be transduced
through the TNFR-associated death domain protein
(TRADD) [15], TNFR-associated factor 2 (TRAF2) [16]
and NF-UB-inducing kinase (NIK) [17], which eventually ac-
tivates the IUB kinases (IKKK, IKKL and IKKQ) [18^22].
Activated IKKK and IKKL phosphorylate serine residues in
the N-terminal region of IUB, resulting in the release of NF-
UB from IUB, allowing NF-UB to translocate to the nucleus
and promote gene transcription. IUBK becomes phosphorylat-
ed in response to TNF treatment and leads to IUBK being
rapidly degraded. IUBL and IUBO are also degraded to some
extent [12].
The mechanism by which TNFRs can activate NF-UB is
not fully understood. TNFR1 through its FADD/TRADD
interaction, is capable of NF-UB activation. Much work has
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focused on the ability of TRAF-2 adapter protein to activate
NF-UB [23]. TRAF-2 binds directly to TNFR2 and indirectly
to TNFR1 so both receptor isotypes are capable of NF-UB
transcriptional activity. Upstream kinases that activate NIK
are still being delineated and the ability of each TNFR to
activate such kinases is presently uncertain. Indeed, a role
for NIK in TNFR triggering of NF-UB has been called into
question as NIK-de¢cient mice are still capable of TNF-
stimulated NF-UB activity [24,25]. More recently, a role for
receptor-interacting protein (RIP), which contains kinase ca-
pabilities, has been shown as a means for NF-UB activation
processes [23]. RIP and TRAF-2 either directly or indirectly
interact with both TNFRs [26]. RIP has also been suggested
to be important in signalling switching by both TNFRs be-
tween c-Jun N-terminal kinase (JNK) activity and NF-UB
transcription activation mechanisms, resulting in proliferative
or apoptotic responses [27].
Surprisingly, little work has addressed the relative contribu-
tion each of the TNFRs has towards TNF-induced NF-UB
activation, with only indirect assessments [28^37]. This is
partly due to the experimental limitations of e⁄ciently acti-
vating TNFR2 which, unlike TNFR1, is poorly activated by
soluble TNF (the form most commonly used experimentally)
[38]. E⁄cient activation of TNFR2 requires membrane-bound
TNF (as is presented in vivo) but can be overcome in the
laboratory with the use of agonistic antisera, such as MR2-1
mAb as used here. TNFR subtype-selective stimulation was
also achieved with mutated protein (‘mutein’) TNFs
(R32WS86T TNFR1-speci¢c mutein ‘R1-TNF’ or D143-
NA145R TNFR2-speci¢c mutein ‘R2-TNF’ [39]). Here, not
only by measuring exogenously generated TNFR2 actions,
but with endogenously expressed TNFRs too, we evaluated
the relative contribution of e⁄ciently activated TNFR1 and
TNFR2 towards NF-UB activation processes.
2. Materials and methods
2.1. Cells
HEK293 wild-type cells were a gift from Mike Ashford, Aberdeen,
UK, and KYM-1 cells were a gift from Terje Espevik, Trondheim,
Norway. Stably expressing HeLa-p75TNFR cells were generated by
injecting human p75TNFR (provided by Werner Lesslauer, Basel,
Switzerland) and pBABE hygromycin-resistant cDNAs into HeLa
cells with an Eppendorf InjectMan microinjection and micromanipu-
lation system as described [40]. Stably transfected HEK293 cells con-
taining 3UNF-UB-luciferase reporter construct (provided by Andrew
Paul, Strathclyde University, UK, and Ron Hay, St. Andrew’s, UK
[41]), or NF-UB-luciferase plus p75TNFR expression, were created by
transfection of the cDNA with pBABE hygromycin resistance cDNA,
using Lipofectamine transfection reagent (Gibco BRL). Colonies of
stable transfectants were selected in Dulbecco’s modi¢ed Eagle’s me-
dium (DMEM) containing 100 Wg/ml hygromycin-B (Boehringer
Mannheim). Stably transfected cell lines were maintained in a culture
of DMEM (1000 mg/ml glucose/no sodium pyruvate) with 10% foetal
calf serum (Helena Biosciences), 4 mM L-glutamine and 50 U/ml
penicillin, 50 Wg/ml streptomycin, using standard sterile techniques.
KYM-1 cells were grown in RPMI 1640 supplemented with 4 mM
L-glutamine, 50 U/ml penicillin, and 50 Wg/ml streptomycin. Transient
transfections of cells with 0.1 Wg NF-UB-dependent reporter, 0.1 Wg
TNFR2 cDNA or 1 Wg of peGFP (enhanced green £uorescence pro-
tein; provided by Gwyn Gould, Glasgow, UK) was introduced into
the cells by Lipofectamine according to the standard transfection
protocol for 3 h before reintroduction to serum-containing medium.
After an overnight incubation, the culture media was replaced with
fresh DMEM containing 10% foetal calf serum. 48 h post-transfec-
tion, the cells were treated with various types of stimuli before being
assayed as described below, or viewed directly on a Bio-Rad Wra-
diance confocal system, as was the case with cells transfected with
the peGFP cDNA construct.
2.2. Fluorescence-activated cell sorting (FACS) analysis
HeLa cells stably over-expressing TNFR2, KYM-1 cells and
HEK293 cells stably expressing NF-UB-luciferase reporter construct
or NF-UB-luciferase plus TNFR2 were grown to approximately 70%
con£uency and dissociated from their culture vessels with 2 ml of
trypsin-free cell dissociation solution (Sigma). Cells were analysed
for TNFR1 or TNFR2 content using mouse monoclonal anti-human
htr-9 or utr-1 respectively, as described [42].
2.3. JNK activity
JNK activity was measured by assessing phosphorylation of its
substrate c-Jun (5-89) linked to a glutathione-S-transferase fusion
protein as described [40].
2.4. Confocal £uorescence microscopy
All cells were treated for the indicated time with either 50 ng/ml
recombinant human TNF, R32WS86T mutated protein TNF
(TNFR1-speci¢c ‘mutein’ termed R1-TNF [39]), D143NA145R TNF
(TNFR2-speci¢c mutein termed R2-TNF) or with TNFR2-speci¢c
agonistic MR2-1 monoclonal antibody (1 Wg/ml)(kindly provided by
Wim Buurman, Maastricht, Netherlands) [43]. Cells were then ¢xed
and analysed as described previously [40].
2.5. Western analysis
Cells were treated with stimuli for the indicated times before West-
ern analysis as previously described [40].
2.6. EMSA (electrophoretic mobility shift assay)
For preparation of nuclear extracts, cells were seeded into 6-well
plates at a concentration of 2U105 cells/ml culture medium and in-
cubated overnight prior to a 1 h treatment with 50 ng/ml recombinant
TNF, R1-TNF, R2-TNF or R2-TNF plus 1 Wg/ml MR2-1 antibody.
Cells were washed in ice-cold PBS and harvested in 100 Wl bu¡er A
(10 mM HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM
dithiothreitol (DTT), 0.2% Nonidet P-40, 0.5 mM AEBSF, 1 mM
sodium orthovanadate, 1 mM NaF, 0.1 mM aprotonin), centrifuged
and the cell pellet resuspended in 50 Wl of bu¡er C (20 mM HEPES,
pH 7.9, 1.5 mM MgCl2, 0.42 M NaCl, 0.5 mM DTT, 0.2 mM EDTA,
25% glycerol) and incubated on ice for 10 min with occasional mixing.
Samples were centrifuged and the concentration of nuclear extract
contained in the supernatant was determined by protein assay (Bio-
Rad). 5 Wg of nuclear extract was used for the EMSA. High-perfor-
mance liquid chromatography-puri¢ed NF-UB oligonucleotide (5P-
AGTTGAGGGGACTTTCCCAGGCGCCTGGGAAAGTCCCCT-
CAACT-3P), obtained from Oswel laboratories, Southampton, UK,
was end labelled with [32P]Q-ATP using T4 polynucleotide kinase.
5 Wg of nuclear extract, 2 Wg poly (dI-dC), 200 ng of labelled probe
and water were incubated in a ¢nal volume of 10 Wl for 20 min at
room temperature. The samples were separated by 17% PAGE in
TBE bu¡er.
2.7. NF-UB luciferase or GFP activity measurements
HEK293 cells, HeLa cells or HeLa-TNFR2 stable expressing cells
were transiently transfected with NF-UB-luciferase reporter construct
using the Lipofectamine transfection protocol outlined above, with
receptor-stimulated luciferase transcription being measured 48 h
post-transfection. Stably expressing NF-UB-luciferase or NF-UB-lucif-
erase plus TNFR2 HEK293 cells were plated into 24-well plates at a
density of 1U105 cells/ml culture media. The cells were incubated for
24 h to reach 80% con£uency before a 6 h treatment with 50 ng/ml
recombinant TNF, R1-TNF, R2-TNF or R2-TNF plus 1 Wg/ml
MR2-1 antibody. NF-UB-stimulated luciferase activity was detected
by washing the cells twice, with ice-cold PBS, adding 200 Wl of ice-
cold lysis bu¡er (25 mM Tris^phosphate, pH 7.8, 8 mM MgCl2, 1 mM
DTT, 1% Triton X-100, 15% glycerol) and incubating on ice for 5 min.
Cell extracts were scraped into 1.5 ml Eppendorf tubes, centrifuged to
pellet cell debris and 100 Wl of the supernatant used to measure lu-
ciferase induction by injecting it with an equal volume of luciferase
bu¡er (lysis bu¡er containing 1 mM ATP, 0.25 mM luciferin (Mol-
gfecular Probes), 1% BSA) in a Berthold LB9501 Lumat luminometer.
Novel NF-UB^humanised renilla GFP (hrGFP) reporter construct
cDNA (Stratagene) was transfected into HeLa-TNFR2 cells.
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24 h post-transfection, TNFR-induced GFP expression was measured
with a £uorescence/visible light microscope set-up or by FACS anal-
ysis, indicating cells which report NF-UB-stimulated gene activity.
3. Results
3.1. Cellular TNFR subtype levels
HeLa human cervical epithelial carcinoma cells and
HEK293 human embryonic kidney cell lines express TNFRs
which are predominately of the TNFR1 subtype. KYM-1 hu-
man rhabdomyosarcoma cells endogenously express high
amounts of both TNFR1 and TNFR2, as judged by htr-9-
and utr-1-speci¢c monoclonal FACS analysis respectively and
isoform-speci¢c [125I]TNF radioligand binding experiments
[40]. HeLa-TNFR2 cell line was generated to stably over-ex-
presses exogenous TNFR2, so as to maximise TNFR2 signal-
ling responses. HeLa, HeLa-TNFR2 and KYM-1 cells possess
approximately 200, 60 000 and 12 000 TNFR2 receptors/cell
respectively. HeLa and HeLa-TNFR2 express some 3000^
4000 TNFR1 receptors/cell, whereas KYM-1 cells express
similar levels of TNFR1 with 8000 TNFR1 receptors/cell [40].
3.2. JNK and NF-UB activation by TNFRs
Soluble TNFs e⁄ciently stimulate TNFR1, however poorly
Fig. 1. TNFR1- and TNFR2-stimulated JNK and NF-UB DNA-binding activities. A: Wild-type HeLa, HeLa-TNFR2 stable cell line or KYM-
1 cell lines were analysed for TNFR1- and TNFR2-stimulated JNK activity as described in Section 2. TNF (from a commercial source), wild-
type TNF (wt-TNF) or mutein TNFs (50 ng/ml) stimulation of JNK activity after 15 min treatment. MR2-1 TNFR2-agonistic monoclonal
antisera was also added where indicated (2 Wg/ml). The results shown are from experiments that are representative of a least three independent
assessments. B: HeLa-TNFR2 stable cell line or KYM-1 cell lines were analysed for TNFR1- and TNFR2-stimulated NF-UB DNA-binding ac-
tivity by EMSA as described in Section 2. TNF, wt-TNF or mutein TNFs þ MR2-1 (at the above concentrations) stimulation of JNK activity
after 60 min treatment. The results shown are from experiments that are representative of a least three independent assessments with essentially
the same ¢ndings.
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activate TNFR2 which requires the membrane-bound form of
TNF for maximal stimulation, however, TNFR2-speci¢c ago-
nistic antisera can be used to mimic membrane-bound TNF
and stimulate TNFR2 [38]. To test the ability of our receptor
subtype-speci¢c agonistic muteins and antisera, we measured
activation of the stress kinase JNK by TNFR1 or TNFR2
(Fig. 1A). Stimulation of TNFR1 leads to e⁄cient JNK acti-
vation, whereas TNFR2 is capable of e⁄ciently activating
JNK activity to maximal levels as judged with 200 nM aniso-
mycin stimulus (not shown). Signi¢cant TNFR2-mediated
JNK activation is observed in HeLa-TNFR2 and KYM-1
cells (which possess reasonable levels of TNFR2) using the
R2-TNF mutein and MR2-1 agonistic antisera stimuli (Fig.
1A). The TNFR-induced JNK activity assays also display the
Fig. 2. TNFR1- and TNFR2-stimulated IUB degradation. A: Wild-type HeLa, HeLa stably expressing TNFR2 and KYM-1 cells were stimu-
lated for 30 min by TNF (50 ng/ml) and/or MR2-1 antisera (2 Wg/ml) before measurement of IUBK protein degradation by Western analysis, as
described in Section 2. A non-speci¢c (n.s.) band generated by the secondary detection antisera is also indicated for comparison. B: Time
course of IUBK and IUBL protein degradation stimulated by TNFR1 or TNFR2 in HeLa-TNFR2 cells using 50 ng/ml R1-TNF or R2-TNF
plus 1 Wg/ml MR2-1 antisera respectively. The results shown are from an experiment that is representative of a least three independent assess-
ments. C: HeLa-TNFR2 cells were stimulated the indicated times with 50 ng/ml TNF and subcellular IUBK protein degradation measured by
confocal microscopy, as described in Section 2. D: Quanti¢ed cytoplasmic confocal £uorescence intensities of IUBK protein degradation stimu-
lated by TNFR1 or TNFR2 using 50 ng/ml R1-TNF or R2-TNF plus 2 Wg/ml MR2-1 antisera respectively. The results shown are from an ex-
periment that is representative of a least two independent assessments.
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reduced ability of soluble TNFRs to activate TNFR2 and the
requirement for agonistic antisera to e⁄ciently activate
TNFR2-mediated JNK activation.
EMSA DNA-binding assays were used to study the activa-
tion of NF-UB protein when induced by TNF or subtype-
speci¢c muteins. Fig. 1B shows the EMSA results of NF-UB
activation in KYM-1 cells and HeLa cells over-expressing
TNFR2 (HeLa-TNFR2), when the cells were treated with
recombinant TNF, TNFR1-speci¢c mutein TNF, TNFR2-
speci¢c mutein TNF alone or in combination with TNFR2-
agonistic antibody MR2-1. Both cell types showed a speci¢c-
ity of NF-UB DNA binding complexes, and was determined
by competition with a 10-fold excess of unlabelled probe, but
not randomised-sequence probe (not shown). The shift of the
NF-UB speci¢c band indicated NF-UB DNA-binding activity
in both cell lines by treatment with TNF and TNFR1-speci¢c
mutein TNF. There was little observed e¡ect in either cell
when TNFR2 activation was performed by mutein and/or
antisera stimuli (6 5% of the activity observed with TNF).
3.3. IUBK and IUBL activation
E⁄cient stimulation of TNFR2 is achieved by stimulatory
agonistic antisera used either alone or in combination with
TNFR2-speci¢c mutein TNF. In Fig. 2, we observed the ac-
tion of maximal stimulatory concentrations of TNF, R1-
TNF, R2-TNF or R2-TNF plus MR2-1 antibody on the ac-
tivation/degradation of IUBK and IUBL. Fig. 2A,B shows the
ability of the TNFR isoform-speci¢c stimuli to e¡ect IUBK
degradation as measured by changes in protein abundance
of IUBs. A useful non-speci¢c immunoreactive band helps to
con¢rm equal protein loading and the speci¢city of the IUBK
antisera band. HeLa-TNFR2 and KYM-1 cells were treated
for 30 min with maximal concentrations of various treatments
and it was noted that both cell types showed IUBK degrada-
tion at 30 min treatment with recombinant TNF (from a
commercial source), wild-type TNF and R1-TNF. In HeLa-
TNFR2 and KYM-1 cells, but not wild-type HeLa cells, there
was degradation of IUBK by TNFR2-speci¢c mutein and ago-
nistic antisera MR2-1. TNFR2 degraded IUBK, but not to the
same complete extent as seen with TNFR1. Curiously, KYM-
1 cells showed slightly better TNFR2-induced IUBK degrada-
tion than HeLa-TNFR2 cells (Fig. 2A), but less TNFR2-in-
duced NF-UB DNA binding capability in the EMSA assay
(Fig. 1B).
These cell lines were treated over varying times with
TNFR1-speci¢c mutein TNF or TNFR2-speci¢c mutein
TNF plus agonistic antibody MR2-1, to observe at which
times each TNFR isotype was having an e¡ect. Treatment
of the HeLa-TNFR2 cell type with R1-TNF revealed a tran-
sient pattern of IUBK degradation observed within 10 min.
IUBK protein returned to control levels after 90 min of
TNFR1 activation with the R1-TNF treatment. The IUBK
degradation in HeLa-TNFR2 cells when treated with
TNFR2-speci¢c stimuli was much less pronounced, with
IUBK protein being slightly degraded by TNFR2, but if any-
thing occurring in a more delayed time-frame than observed
with TNFR1 stimulation (Fig. 2B). HeLa-TNFR2 cells were
treated with similar treatments to observe their e¡ect on IUBL
degradation. TNFR1 mutein showed marked degradation of
IUBL over 120 min of treatment, with degradation occurring
less rapidly than is seen with IUBK protein, but no e¡ect on
IUBL degradation was observed when cells were treated with
TNFR2-speci¢c mutein over the same time course (Fig. 2B).
These observations were con¢rmed using FACS analysis to
measure IUBL degradation; furthermore, similar patterns of
TNFR1 and TNFR2-induced IUB protein degradations were
observed in the KYM-1 cell line (data not shown).
Confocal microscopy was used to measure ligand-induced
subcellular redistribution and degradation of IUBK protein.
As can be seen in HeLa-TNFR2 cells (Fig. 2C,D), treatment
with TNF or R1-TNF mutein show degradation of speci¢c
IUBK immuno£uorescence staining from the cytoplasm of the
cells after 30 min treatment. When cells were treated with
TNFR2-speci¢c stimuli, less cytoplasmic IUBK degradation
was observed, even after 60 min of treatment (not shown).
From these results, it would indicate that signalling mostly
through the TNFR1 by TNF and TNFR1-speci¢c mutein
TNF is required for the noted degradation of IUBK protein.
It would appear that the maximal amount of TNF-induced
IUBK degradation requires both TNFRs to be activated fully,
with TNFR1 activation not giving 100% of the TNF response,
and TNFR2 activation always giving some minimal e¡ect.
This is in spite of TNFR2 being fully active when measuring
TNFR2-mediated JNK activation in HeLa-TNFR2 and
KYM-1 cells (Fig. 1A).
3.4. TNFR-stimulated NF-UB transcription
To observe the level of NF-UB gene transcriptional activity,
we transiently transfected NF-UB-luciferase gene reporter con-
struct into our cells and assayed for TNFR-stimulated lucif-
erase activity (Fig. 3A). We also looked at transient trans-
fection of HEK293 human embryonic kidney cells which
give enhanced transfection and transcription of cDNA vec-
tors. HEK293 cells express endogenous TNFR1 protein.
Also included in our transient transfection studies was
HEK293 cells stably expressing human TNFR2 (HEK293-
TNFR2). Transient transfection of NF-UB reporter construct
into HeLa-TNFR2, HEK293 or HEK293-TNFR2 cells re-
vealed that the majority of NF-UB gene transcription is
once again stimulated by TNFR1, with a lesser amount of
activation (consistently 6 15%) stimulated by TNFR2. Even
though TNFR2 stimulation could e⁄ciently trigger JNK ac-
tivity, we wanted to be sure that low levels of TNFR2 expres-
sion (as is the case with parental HeLa and HEK293 cells)
was not the cause for the lesser NF-UB activity observed by
TNFR2 compared to TNFR1-stimulated responses.
Unfortunately, our attempts to transiently transfect KYM-
1 cells were unsuccessful. We discovered that KYM-1 cells did
not produce high levels of NF-UB activity, so we investigated
the transfection e⁄ciency of all our cell lines with peGFP (red
shifted variant, eGFP) cDNA. The peGFP construct was
easily visualised with confocal microscopy when excited with
blue light (excitation 488 nm/emission 509 nm). HeLa-TNFR2
cells showed on average V60% transient transfection e⁄-
ciency up to 48 h post-transfection, however, KYM-1 cells
showed little (typically 6 1%) transfection e⁄ciency.
HEK293 cells showed on average s 90% transfection e⁄-
ciency with peGFP and so transient transfection of the NF-
UB-luciferase construct would pose no signi¢cant problems
with either the HeLa TNFR2 stable cell line or wild-type
HEK293 cell line. E¡orts to transiently transfect KYM-1 cells
were fruitless. Equally, repeated e¡orts to stably transfect NF-
UB-luciferase reporter into KYM-1 cells resulted in zero cell
survival. A similar pattern of receptor isotype-speci¢c NF-UB
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activation was measured by transient transfection of NF-UB-
luciferase reporter construct into HEK293 cells or HEK293-
TNFR2 cells, with very little detectable TNFR2-stimulation
of NF-UB-luciferase activity (Fig. 3A). The majority of stim-
ulation of NF-UB-luciferase being mediated by TNFR1 in
HEK293 or HEK293-TNFR2 cells.
As KYM-1 cells are vulnerable to the toxic actions of Lipo-
fectamine, we chose to stably transfect HEK293 cells and
HEK293-TNFR2 cells with NF-UB-luciferase reporter con-
struct, as a comparison to HeLa-TNFR2 cells (Fig. 3B,C),
so as to be certain that the inability of TNFR2 to e⁄ciently
activate NF-UB gene transcription in our cells was not due to
poor expression of TNFR2 levels (or NF-UB reporter con-
struct. Fig. 3B shows by FACS analysis the stable expression
of TNFR2 in our HEK293-TNFR2 cells, which is not present
in parental HEK293 cells. No TNF-stimulated luciferase ac-
tivity is detectable in HEK293 cells not expressing NF-UB
reporter construct (not shown). The NF-UB-luciferase results
from both types of transfections of HEK293 cells, either tran-
siently or stably, gave very similar results to those gained for
the HeLa-TNFR2 cells transiently transfected with the NF-
UB-luciferase construct, i.e. TNFR2-stimulation accounted for
Fig. 3. TNFR1- and TNFR2-stimulated NF-UB-luciferase gene transcription activity. TNFR1- and TNFR2-stimulated NF-UB-luciferase report-
er construct measurements (A) by transient transfection reporter construct measured 48 h post-transfection, as described in Section 2, or (C) in
stable NF-UB-luciferase reporter construct-containing cells. The TNFR1- and TNFR2-speci¢c stimuli, at the same concentrations as used in
Fig. 1, were applied for 6 h before NF-UB-driven luciferase measurement in relative light units (RLU). The results shown are the mean þ S.D.
of quadruplicate determinations from experiments that are representative of a least three independent assessments. None of the TNFR2-stimu-
lated responses above control report levels were found to be statistically signi¢cant (Ps 0.05, Student’s t-test). B: FACS analysis of TNFR1
and TNFR2 cell surface protein expression of parental HEK293 cells or HEK293 cells stably expressing TNFR2 or TNFR2 plus NF-UB-lucif-
erase reporter construct.
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approximately only 10% of the achievable TNFR-stimulated
NF-UB activity.
Similar pro¢les of TNFR-induced NF-UB reporter con-
struct activity was seen using transient transfection of cDNAs
expressing hrGFP gene rather than ¢re£y luciferase (Fig. 4).
This mode of reporter construct has the advantage that the
cells do not need to be destroyed to measure the report (as is
the case with luciferase activity), but the report is measured in
living cells in a more ‘in situ’ circumstance, and subsequent
cellular actions (e.g. apoptosis) can be observed from the re-
porting cell. These data in Fig. 4 show that HeLa-TNFR2
cells treated with TNFR1- or TNFR2-speci¢c stimuli lead
to NF-UB gene activity in a time-dependent manner with sig-
ni¢cant stimulation of NF-UB-dependent transcription observ-
able in as little as 2 h of TNF treatment. FACS analysis of
TNFR-stimulated GFP expression again revealed predomi-
nately TNFR1-stimulated activity with markedly less
TNFR2-activated NF-UB gene stimulation (not shown).
4. Discussion
In this study, we have observed that both endogenous and
exogenous TNFR1 and TNFR2 receptor subtypes stimulate
various aspects of NF-UB activation processes. It was previ-
ously known that both receptor isoforms are capable of acti-
vating NF-UB [1], however, this is the ¢rst report to quantitate
the relative contribution of each TNFR. The ability of
TNFR1 to activate NF-UB appears to account for the vast
majority of TNF-stimulated NF-UB transcription factor acti-
vation (presumably through TRADD/FADD interaction).
However, we consistently observe that TNFR1-mediated acti-
vation does not account for all TNF-stimulated NF-UB acti-
vation, suggesting a contributory role for TNFR2. This sug-
gests that a simple ‘ligand passing’ role for TNFR2 (merely
presenting TNF ligand to TNFR1 [7]) is not the role for
TNFR2 in NF-UB activation. Indeed, TNFR2 directly binds
the TRAF-2 intracellular adapter protein (a known stimulator
of NF-UB), which also binds indirectly to TNFR1. Another
adapter protein which binds both TNFRs is RIP (-1, -2 and
-3), 57^74 kDa proteins which contain kinase domains [23].
RIP is capable of transducing both JNK and NF-UB activa-
tion by both TNFRs and is thought to be a possible switch in
TNFR2-mediated cell death-enhancing or proliferative NF-UB
actions, at least in T cells [27]. Another signalling protein
thought to activate NF-UB is NIK which phosphorylates
IKKs, resulting in activation of IUBK and IUBL, however,
the architecture of TNFR1 and TNFR2 activation of this
extracellular signal-regulated kinase is unclear. Moreover,
transgenic mice lacking NIK were still capable of TNF-in-
duced NF-UB activation, suggesting more complex adaptive
processes in TNFR-induced NF-UB gene transcription [11].
Despite the precise mechanism of TNFR1 and TNFR2 ac-
tivation of NF-UB being not fully understood, it is clear from
our studies here that the majority of soluble TNF-mediated
NF-UB activation occurs through TNFR1, with TNFR2 play-
ing a minor role. This does not take into account ¢ndings
which uncovered that soluble TNF e⁄ciently activates
TNFR1, but poorly activates TNFR2 [38,44]. The mem-
brane-bound form of TNF (as is presented to cells in vivo)
e⁄ciently activates both TNFR1 and TNFR2. Therefore, the
contribution of each TNFR towards NF-UB activation in vivo
may be more reliant on TNFR2. Our use here of agonistic
antisera to e⁄ciently stimulate TNFR2 provides us with a
fairer assessment of the relative functional contribution of
TNFR1 and TNFR2. Given that these stimuli may lead to
fully active JNK activity by both TNFRs, it is clear that stim-
ulation of NF-UB is predominately through TNFR1. TNFR2
is capable of NF-UB activation (as has been shown by others)
but its actions, even in cells expressing large amounts of
TNFR2, is over-exaggerated when compared to TNFR1-
mediated NF-UB activation.
Partly due to the inability of soluble TNFs to e⁄ciently
activate TNFR2, the exact role of TNFR2 in TNF signalling
is not fully understood. Some workers claim that endoge-
nously expressed TNFR2 stimulates NF-UB activity [29,31],
whereas others claim it to be an artefact of exogenous over-
expression of the receptor isotype [4]. Perhaps experimental
circumstances do not favour investigations of TNFR2-medi-
ated NF-UB activation, with many researchers opting for
over-expression for their studies. For example, over-expres-
sion studies in HEK293 cells led to TNFR2-induced NF-UB
activation, even in the absence of ligand [45,46]. We did not
observe the same agonist-independent TNFR2-induced NF-
UB activation in HEK293 cells here. How the exogenous re-
ceptor compares to other natural cell types which are not
genetically engineered for over-expression is a valid consider-
ation. Moreover, the cell type has been an important factor in
assessing the TNFR-induction of NF-UB, with many cells
Fig. 4. TNFR1- and TNFR2-stimulated NF-UB^hrGFP gene tran-
scription activity. TNFR1- and TNFR2-stimulated NF-UB^hrGFP
reporter construct measurements (A) by transient transfection re-
porter construct measured 24 h post-transfection, as described in
Section 2. B: The TNFR1- and TNFR2-speci¢c stimuli were applied
for the indicated time before NF-UB-driven hrGFP measurement by
counting the percent of total cells displaying £uorescence. Stimuli at
the same concentrations used in Fig. 1, were applied as indicated.
The results shown are the mean þ S.D. of triplicate determinations.
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lacking the necessary signalling machinery to allow observable
TNFR stimulation of NF-UB [4,31].
The ¢ndings here, shed new light on the relative contribu-
tion each of the TNFR subtypes plays in cells expressing
TNFR1 and TNFR2. As TNFR1 levels remain relatively con-
stant, with a wide regulation of TNFR2 protein expression in
cells experiencing di¡erent stimuli or pathological conditions,
the contribution each of the TNFR subtypes has towards a
TNF-stimulated NF-UB response may alter. Thus, the role of
the two TNFRs in TNF-stimulated NF-UB-mediated pro-in-
£ammatory and anti-apoptotic cellular actions may need to be
addressed for each cell type under varying cellular conditions.
But, it is clear that even given a large excess of TNFR2 over
TNFR1 expression in a cell, the vast majority of the TNF-
induced NF-UB signal will be mediated by TNFR1 rather
than TNFR2.
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